ProSomnus, Inc.
OSAPQ
Other OTC0.01
USD
+0.00
- -
CIK
0001934064
ISIN
US50535E1082
CUSIP
50535E108
Return %
Stock
S&P500
1Y
-98.68
26.53
3Y
-99.85
76.60
5Y
-99.85
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Leonard Liptak
- Full Time Employees
- 136
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 5675 Gibraltar Drive Pleasanton CA United States of America 94588
- IPO Date
- Jul 28, 2021
- CIK
- 0001934064
- Website
- prosomnus.com
- Similar Companies
- Business
- ProSomnus, Inc. (OSAPQ) operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea (OSA), a condition affecting over one billion people worldwide and linked to comorbidities such as heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. The company's core products include FDA-cleared Precision Oral Appliance Therapy (OAT) devices, such as the ProSomnus EVO Sleep and Snore Device for reducing nighttime snoring and mild to moderate OSA; the EVO [PH] Sleep and Snore device; the recently FDA-registered HWO2 device for enhanced sleep wellness tracking; and the new EVO Guided appliance, which features embedded sensors for remote patient monitoring by sleep physicians. These patient-specific, digitally milled maxillary and mandibular aligners with twin-mated posts reposition and stabilize the jaw to improve airflow, offering a non-invasive, comfortable alternative to CPAP machines with no electricity required, high portability, low maintenance, and coverage by commercial insurance, Medicare, TRICARE, and various government plans representing over 200 million lives. ProSomnus sells its devices to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and integrated healthcare providers through a direct sales force, primarily targeting the U.S. market with plans for international expansion. Founded in 2016 and headquartered in Pleasanton, California, the company went public in 2022 via a business combination with Lakeshore Acquisition I Corp but transitioned back to private status following a voluntary Chapter 11 restructuring in May 2024, which concluded in August 2024 with court approval. This reorganization reduced debt by approximately 60%, eliminated public company costs of $4-6 million annually, deferred debt amortization, paid creditors in full including unsecured ones, and secured $20 million in new financing from investors like SMC Holdings II, CETUS Capital VI, and others to fund operations, sales team growth, and next-generation sensor-equipped devices. In 2025, ProSomnus achieved FDA registration for its HWO2 device, launched EVO Guided, appointed Jason Orchard as CFO, earned EU-U.S. Data Privacy Framework certification as the first major sleep medicine firm for compliant cross-border data transfers, and ranked on the Inc. 5000 list of fastest-growing U.S. private companies for the fourth year (#79 in manufacturing, driven by organic demand). The company, led by CEO Len Liptak, continues to innovate in dental sleep medicine with over a dozen clinical trials demonstrating superior efficacy, adherence, and patient preference.